Esophageal Cancer
Conditions
Keywords
stage IIA esophageal cancer, stage IIB esophageal cancer, stage IIIA esophageal cancer, stage IIIB esophageal cancer, stage IIIC esophageal cancer, stage IV esophageal cancer
Brief summary
RATIONALE: Drugs used in chemotherapy, such as S-1 and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy together with more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving S-1 and cisplatin together with radiation therapy works in treating patients with stage IIA, stage III, or stage IVA esophageal cancer that can be removed by surgery.
Detailed description
OBJECTIVES: Primary * To evaluate response rate in patients with stage IIA-IVA resectable esophageal cancer treated with chemoradiotherapy comprising S-1, cisplatin, and radiotherapy. Secondary * To evaluate overall survival of these patients. * To evaluate progression-free survival of these patients. * To evaluate toxicity in these patients. * To correlate initial squamous cell carcinoma antigen and C-reactive protein with response and survival in these patients. OUTLINE: Patients receive oral S-1 twice weekly, cisplatin IV over 2 hours on day 1, and undergo radiotherapy 5 days a week in weeks 1 and 2. Treatment repeats every 3 weeks for 2 courses. Tumor tissue samples are collected by esophagoscopy with biopsy and brushings for analysis of initial squamous cell carcinoma antigen and C-reactive protein correlation with response and survival. After completion of study treatment, patients are followed for 6 months.
Interventions
DRUGcisplatin
OTHERcytology specimen collection procedure
PROCEDUREendoscopic biopsy
Sponsors
Yonsei University
Study design
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed carcinoma of the esophagus * Stage IIA-IVA disease * Resectable disease * Measurable disease, defined as at least 1 measurable lesion by RECIST criteria * No known brain metastasis PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Life expectancy \> 3 months * ANC ≥ 1,500/uL * Hemoglobin ≥ 9.0 g/dL (transfusion correction allowed) * Platelets ≥ 100,000/uL * Creatinine \< 1.5 mg/dL * Total bilirubin \< 2 times upper limit of normal (ULN) * ALT/AST \< 3 times ULN * Fertile patients must use effective contraception * Not pregnant or nursing * Able to take oral medication * No active peptic ulcer disease * No known hypersensitivity to study drugs * No serious uncontrolled systemic intercurrent illness, including the following: * Poorly controlled diabetes * Active infection * No history of significant neurological or mental disorder, including seizures or dementia * No malignancy within the past 5 years, except carcinoma in situ of the cervix, or nonmelanomatous carcinoma of the skin * No active cardiac disease uncontrolled by therapy * No myocardial infarction within the past 12 months * No interstitial lung disease or extended fibrosis of lung PRIOR CONCURRENT THERAPY: * No prior chemotherapy or radiotherapy for esophageal cancer * No prior surgical procedure affecting absorption * No concurrent flucytosine or other fluoropyrimidine-group anticancer drugs * No concurrent systemic chemotherapy, investigational drug, or radiotherapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival | — |
| Progression-free survival | — |
| Toxicity | — |
| Initial squamous cell carcinoma antigen and C-reactive protein correlation with response and survival | — |
Countries
South Korea
Outcome results
None listed